Mizuho analyst Uy Ear raised the firm’s price target on Neurocrine to $116 from $113 and keeps a Neutral rating on the shares following the better than expected Q3 report. The firm sees higher overall Ingrezza sales forecasts through 2028 given the strong growth momentum, but adjusted Ingrezza sales for the potential impact from Inflation Reduction Act price negotiation.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NBIX:
- Neurocrine price target raised to $128 from $123 at RBC Capital
- Neurocrine price target raised to $100 from $95 at Piper Sandler
- Neurocrine sees 2023 Ingrezza net sales $1.82B-$1.84B
- Neurocrine reports Q3 non-GAAP EPS $1.54, consensus 98c
- Neurocrine Biosciences Reports Third Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance